MCID: EPL164
MIFTS: 69

Epilepsy

Categories: Neuronal diseases, Rare diseases, Genetic diseases

Aliases & Classifications for Epilepsy

MalaCards integrated aliases for Epilepsy:

Name: Epilepsy 12 76 54 55 43 3 44 15 63 40 73
Epileptic Syndrome 12
Epilepsy Syndrome 12

Classifications:



Summaries for Epilepsy

NINDS : 54 The epilepsies are a spectrum of brain disorders ranging from severe, life-threatening and disabling, to ones that are much more benign. In epilepsy, the normal pattern of neuronal activity becomes disturbed, causing strange sensations, emotions, and behavior or sometimes convulsions, muscle spasms, and loss of consciousness. The epilepsies have many possible causes and there are several types of seizures. Anything that disturbs the normal pattern of neuron activity—from illness to brain damage to abnormal brain development—can lead to seizures. Epilepsy may develop because of an abnormality in brain wiring, an imbalance of nerve signaling chemicals called neurotransmitters, changes in important features of brain cells called channels, or some combination of these and other factors. Having a single seizure as the result of a high fever (called febrile seizure) or head injury does not necessarily mean that a person has epilepsy. Only when a person has had two or more seizures is he or she considered to have epilepsy. A measurement of electrical activity in the brain and brain scans such as magnetic resonance imaging or computed tomography are common diagnostic tests for epilepsy.

MalaCards based summary : Epilepsy, also known as epileptic syndrome, is related to myoclonic epilepsy of unverricht and lundborg and epilepsy, myoclonic juvenile, and has symptoms including back pain, headache and pain. An important gene associated with Epilepsy is EPM2A (EPM2A, Laforin Glucan Phosphatase), and among its related pathways/superpathways are Transmission across Chemical Synapses and L1CAM interactions. The drugs Clobazam and Methylprednisolone have been mentioned in the context of this disorder. Affiliated tissues include temporal lobe, brain and testes, and related phenotypes are Resistant to vaccinia virus (VACV-A4L) infection and behavior/neurological

Disease Ontology : 12 A brain disease that is characterized by the occurrance of at least two unprovoked seizures resulting from a persistent epileptogenic abnormality of the brain that is able to spontaneously generate paroxysmal activity and typically manifested by sudden brief episodes of altered or diminished consciousness, involuntary movements, or convulsions.

MedlinePlus : 43 Epilepsy is a brain disorder that causes people to have recurring seizures. The seizures happen when clusters of nerve cells, or neurons, in the brain send out the wrong signals. People may have strange sensations and emotions or behave strangely. They may have violent muscle spasms or lose consciousness. Epilepsy has many possible causes, including illness, brain injury, and abnormal brain development. In many cases, the cause is unknown. Doctors use brain scans and other tests to diagnose epilepsy. It is important to start treatment right away. There is no cure for epilepsy, but medicines can control seizures for most people. When medicines are not working well, surgery or implanted devices such as vagus nerve stimulators may help. Special diets can help some children with epilepsy. NIH: National Institute of Neurological Disorders and Stroke

PubMed Health : 63 About epilepsy: In epilepsy, certain areas of the brain or all areas of the brain are overactive, sending too many signals. This results in seizures, sometimes also referred to as epileptic fits. Epileptic seizures can take different forms. They may cause only a few muscles to twitch, for instance, or they may cause your whole body to convulse (shake uncontrollably) and lead to loss of consciousness.Epilepsy can arise at any age. Some people have their first seizure in childhood, and others have their first seizure in older age. There are usually no physical symptoms in between seizures. But the constant fear of having another seizure may affect your work and private life.Medication can help to prevent seizures and maintain a good quality of life. Unfortunately, medication doesn't always help, though: About 3 out of 10 people still have regular seizures. This makes it particularly difficult for them to live with the condition.

Wikipedia : 76 Epilepsy is a group of neurological disorders characterized by epileptic seizures. Epileptic seizures... more...

Related Diseases for Epilepsy

Diseases in the Epilepsy family:

Benign Familial Infantile Epilepsy Depdc5-Related Epilepsy

Diseases related to Epilepsy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1113)
# Related Disease Score Top Affiliating Genes
1 myoclonic epilepsy of unverricht and lundborg 34.8 CSTB EPM2A
2 epilepsy, myoclonic juvenile 34.8 CACNB4 EFHC1
3 myoclonic astatic epilepsy 34.6 SCN1A SLC2A1
4 myoclonic epilepsy of lafora 34.6 CSTB EPM2A NHLRC1
5 myoclonic epilepsy of infancy 34.5 GABRG2 SCN1A
6 benign familial infantile epilepsy 34.5 CHRNA2 KCNQ3 SCN1B
7 autosomal dominant nocturnal frontal lobe epilepsy 34.5 CHRNA2 CHRNA4 CHRNB2
8 generalized epilepsy with febrile seizures plus, type 1 34.4 SCN1A SCN1B
9 epilepsy, nocturnal frontal lobe, 3 34.3 CHRNA4 CHRNB2
10 autosomal dominant epilepsy with auditory features 34.3 LGI1 RELN
11 generalized epilepsy with febrile seizures plus 34.3 EFHC1 GABRA1 GABRG2 KCNQ3 SCN1A SCN1B
12 temporal lobe epilepsy 34.3 LGI1 RELN SCN1B
13 progressive myoclonus epilepsy 34.2 CSTB EPM2A NHLRC1
14 epilepsy with generalized tonic-clonic seizures 34.1 CSTB EFHC1 SCN1A
15 autosomal dominant nocturnal frontal lobe epilepsy 2 34.1 CHRNA4 CHRNB2
16 febrile infection-related epilepsy syndrome 34.1 POLG SCN1A
17 juvenile absence epilepsy 34.1 EFHC1 GABRA1
18 myoclonus epilepsy 33.9 CSTB EPM2A NHLRC1
19 visual epilepsy 33.9 CLN8 EPM2A NHLRC1
20 epileptic encephalopathy, early infantile, 6 33.9 GABRA1 GABRB3 GABRG2 KCNQ3 SCN1A SCN1B
21 epilepsy, nocturnal frontal lobe, 1 33.8 CHRNA2 CHRNA4 CHRNB2 GABRG2 KCNQ3 SCN1A
22 childhood absence epilepsy 33.7 CHRNA4 EFHC1 GABRA1 GABRB3 GABRG2 SCN1B
23 epilepsy, familial temporal lobe, 1 33.7 LGI1 RELN
24 early onset absence epilepsy 33.7 CHRNB2 SCN1B SLC2A1
25 epilepsy, idiopathic generalized 10 33.6 CACNB4 CHRNA4 CSTB EFHC1 GABRA1 GABRB3
26 unverricht-lundborg syndrome 33.5 CSTB EFHC1 EPM2A KCNQ3 NHLRC1
27 focal epilepsy 33.5 CHRNA2 CHRNA4 CHRNB2 GABRG2 GRIN2A LGI1
28 benign epilepsy with centrotemporal spikes 33.5 CSTB EPM2A GABRG2 GRIN2A KCNQ3 RELN
29 early myoclonic encephalopathy 33.5 CSTB EPM2A GABRG2 SCN1A SCN1B
30 seizures, benign familial infantile, 3 33.4 CHRNA4 GABRG2 KCNQ3 SCN1A SCN1B
31 lennox-gastaut syndrome 33.2 GABRA1 GABRB3 SCN1A SLC2A1
32 mental retardation, x-linked, syndromic, hedera type 33.2 GABRA1 LGI1
33 epileptic encephalopathy, early infantile, 15 32.9 GABRB3 KCNQ3 SCN1A
34 myoclonus 32.6 CSTB EPM2A NHLRC1 SLC2A1
35 epilepsy, idiopathic generalized 32.3 CACNB4 CHRNA4 CHRNB2 EFHC1 GABRA1 GABRG2
36 febrile seizures 31.6 CHRNA4 CHRNB2 GABRG2 SCN1A SCN1B
37 status epilepticus 31.3 LGI1 POLG SCN1A
38 disease of mental health 30.5 CHRNA4 GRIN2A RELN
39 psychotic disorder 30.4 GABRA1 GABRB3 RELN
40 epilepsy, pyridoxine-dependent 12.3
41 ceroid lipofuscinosis, neuronal, 8, northern epilepsy variant 12.3
42 centralopathic epilepsy 12.2
43 epilepsy-aphasia spectrum 12.2
44 epilepsy, familial focal, with variable foci 1 12.2
45 photosensitive epilepsy 12.2
46 epilepsy, progressive myoclonic 7 12.2
47 benign familial neonatal epilepsy 12.2
48 epilepsy, progressive myoclonic, 6 12.2
49 myoclonic epilepsy, familial infantile 12.2
50 epilepsy, juvenile absence 1 12.2

Graphical network of the top 20 diseases related to Epilepsy:



Diseases related to Epilepsy

Symptoms & Phenotypes for Epilepsy

UMLS symptoms related to Epilepsy:


back pain, headache, pain, sciatica, seizures, syncope, tremor, chronic pain, vertigo/dizziness, non-epileptic convulsion, sleeplessness

GenomeRNAi Phenotypes related to Epilepsy according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Resistant to vaccinia virus (VACV-A4L) infection GR00351-A-1 9.23 CACNB4 CSTB EFHC1 GABRA1 GRIN2A NHLRC1

MGI Mouse Phenotypes related to Epilepsy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.36 RELN CLN8 GABRG2 CSTB SCN1A GRIN2A
2 growth/size/body region MP:0005378 10.21 GABRB3 RELN GABRG2 CSTB SCN1A KCNQ3
3 mortality/aging MP:0010768 10.2 GABRB3 RELN CLN8 GABRG2 SCN1A KCNQ3
4 nervous system MP:0003631 10.16 RELN CLN8 GABRG2 CSTB SCN1A GRIN2A
5 muscle MP:0005369 9.91 CHRNB2 RELN CSTB EFHC1 CACNB4 EPM2A
6 no phenotypic analysis MP:0003012 9.56 GABRB3 CSTB SCN1B SLC2A1 NHLRC1 CHRNA4
7 reproductive system MP:0005389 9.28 POLG CHRNB2 GABRB3 CLN8 RELN GABRG2

Drugs & Therapeutics for Epilepsy

PubMedHealth treatment related to Epilepsy: 63

The most suitable kind of treatment for a specific person will depend on the type of epilepsy they have and the course of their disease so far. Epilepsy is usually treated with medication known as anti-epileptic drugs (AEDs). These include various medications from different groups of drugs. If a certain medication doesn’t work when a low dose is used, the dose can be increased. If it still doesn’t work, a medication from a different group of drugs can be tried out or several medications can be used together.Seizures are often one-off events so no treatment is needed at first. People usually only start treatment if they have a second seizure. But certain people, for instance those with a brain disease, are more likely to have further seizures. In those cases it might be a good idea to start treatment after the first seizure. This will greatly depend on the person’s individual situation. It is important to discuss all the options with your doctor.People who decide to take medication usually take it for many years. Some people can try to stop taking medication after a while if they have not had any seizures for several years. Others have to take medication for the rest of their lives.If seizures can’t be prevented with medication, a surgical procedure may be considered. The options include:Brain surgery: If someone has partial seizures and it is clear which part of the brain is triggering them, that part of the brain can be surgically removed. But this is not always possible.Vagus nerve stimulation: In this procedure, a pacemaker-like device is implanted under the skin of your chest, where it produces electrical signals. It is connected to the vagus nerve in your neck and is meant to prevent the nerve cells from being too active.The treatment is overseen by a neurologist. Children and teenagers with epilepsy will see a pediatric neurologist. Some of the diagnostic tests and treatments are often carried out in a hospital. There are outpatient facilities and clinics that specialize in treatments for people with epilepsy (e.g. epilepsy centers, specialized hospital departments or doctors’ practices). These are particularly suitable if you have a specific problem, if the diagnosis is not clear, or if you keep on having seizures despite treatment.When people with epilepsy have seizures they do not usually need treatment. The most important thing that helpers can do is stay calm and prevent injury. If the seizure lasts longer than five minutes or if several seizures occur within a short space of time, the emergency services should be informed (e.g. by calling 112 in Germany and most European countries, or 911 in the U.S.). Severe epileptic seizures may require a hospital stay.

Drugs for Epilepsy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 585)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clobazam Approved, Illicit Phase 4,Phase 3,Phase 2 22316-47-8 2789
2
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
3
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
4
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 84057-84-1 3878
5
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 99-66-1 3121
6
Acetazolamide Approved, Vet_approved Phase 4,Phase 2,Phase 3 59-66-5 1986
7
Carbamazepine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 298-46-4 2554
8
Clonazepam Approved, Illicit Phase 4,Phase 3,Phase 2 1622-61-3 2802
9
Ethosuximide Approved Phase 4,Phase 3 77-67-8 3291
10
Felbamate Approved Phase 4 25451-15-4 3331
11
Gabapentin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 60142-96-3 3446
12
Nitrazepam Approved Phase 4,Phase 2 146-22-5 4506
13
Oxcarbazepine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 28721-07-5 34312
14
Phenobarbital Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-06-6 4763
15
Phenytoin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 57-41-0 1775
16
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1 148553-50-8 5486971
17
Tiagabine Approved, Investigational Phase 4,Phase 1 115103-54-3 60648
18
Topiramate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 97240-79-4 5284627
19
Vigabatrin Approved Phase 4,Phase 3,Phase 2,Not Applicable 68506-86-5, 60643-86-9 5665
20
Zonisamide Approved, Investigational Phase 4,Phase 3 68291-97-4 5734
21 Piracetam Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7491-74-9
22
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59467-70-8 4192
23
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 2078-54-8 4943
24
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 64-17-5 702
25
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 56-12-2 119
26
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
27
Biperiden Approved, Investigational Phase 4,Phase 3 514-65-8 2381
28
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 439-14-5 3016
29
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
30
Droperidol Approved, Vet_approved Phase 4 548-73-2 3168
31
Lorazepam Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 846-49-1 3958
32
Lacosamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 860352-01-8, 175481-36-4 219078
33
Eslicarbazepine acetate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 75970-99-9, 236395-14-5 123618
34
Morphine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 57-27-2 5288826
35
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 1994-09-7, 94-09-7 2337
36
Tranexamic Acid Approved Phase 4,Phase 3 1197-18-8 5526
37
Everolimus Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 159351-69-6 6442177
38
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 22916-47-8 4189
39
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 53123-88-9 5284616 6436030 46835353
40
Amitriptyline Approved Phase 4,Phase 3 50-48-6 2160
41
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
42
Levonorgestrel Approved, Investigational Phase 4,Phase 1 797-63-7, 17489-40-6 13109
43
Citalopram Approved Phase 4,Not Applicable 59729-33-8 2771
44
Clevidipine Approved, Investigational Phase 4 167221-71-8
45
Hydralazine Approved Phase 4 86-54-4 3637
46
Labetalol Approved Phase 4 36894-69-6 3869
47
Sertraline Approved Phase 4,Phase 3,Not Applicable 79617-96-2 68617
48
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
49
Norepinephrine Approved Phase 4 51-41-2 439260
50
Bupropion Approved Phase 4,Phase 3 34841-39-9, 34911-55-2 444

Interventional clinical trials:

(show top 50) (show all 1714)
# Name Status NCT ID Phase Drugs
1 Clobazam Adjunctive Treatment of Adults With Refractory Focal Epilepsy Unknown status NCT02726919 Phase 4 Clobazam
2 The Impact of Reducing Overtreatment on Quality of Life in Children With Refractory Epilepsy Unknown status NCT00647322 Phase 4
3 Immunotherapy in Intractable Cryptogenic Epilepsy Patients With Autoimmune Antibody Unknown status NCT02695797 Phase 4 Prednisolone
4 Hormone Profiles in Adults With Newly Diagnosed Epilepsy Unknown status NCT00137709 Phase 4 Sodium valproate;Lamotrigine
5 Ketogenic Diet vs.Antiepileptic Drug Treatment in Drug Resistant Epilepsy Unknown status NCT00552526 Phase 4 Antiepileptic drug (AED)
6 Study to Improve the Treatment of Epilepsy (SITE) Unknown status NCT00133081 Phase 4 All registered antiepileptic drugs
7 BEEP Follow Up: Evaluation of Repeatability of Lamotrigine Pharmacokinetics in Epileptic Patients Unknown status NCT02404168 Phase 4 lamotrigine (brand Lamictal);lamotrigine (generic Teva)
8 Compare Tolerability of an Overnight Switch to Gradual Switch Between Two Different Forms of Depakote Unknown status NCT00312676 Phase 4
9 A Trial of Generic Substitution of Antiepileptic Drugs Unknown status NCT02429596 Phase 4 Experimental
10 Effects on the Diagnostic Accuracy of Magnetic Imaging Angiographies of the Supra-Aortic Vessels by Three Different Magnetic Resonance Contrast Agents in Patients Unknown status NCT00132223 Phase 4 Contrast agent
11 Levetiracetam Treatment of Children With Subclinical Sleep-Activated Epileptiform Activity (SSEA) Unknown status NCT00393614 Phase 4 levetiracetam
12 Melatonin Versus Placebo in the Lennox-Gastaut Syndrome: Neurophysiological and Neuropsychological Effects Unknown status NCT01370486 Phase 4 melatonin;placebo
13 Comparison of Oral 30 % Dextrose and iv Midazolam Sedation During MRI in Neonates Unknown status NCT02645279 Phase 4 IV midazolam
14 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
15 Clinical Study of Xingnaojing for the Treatment of Convulsive Diseases Unknown status NCT00796380 Phase 4 Xingnaojing
16 Treatment for Alcohol Dependence With Gabapentin Unknown status NCT02771925 Phase 4 Gabapentin 2g/day divided in two doses for 24 weeks;Placebo 2g/day divided in two doses for 24 weeks
17 The Benefit of Prophylactic Anticonvulsant in Post Cardiac Arrest Syndrome With Induced Mild Hypothermia Unknown status NCT01083784 Phase 4 Use of prophylactic anticonvulsants (valproate, clonazepam);Control group
18 Optimization of Procedural Sedation Protocol Used for Dental Care Delivery in People With Mental Disability Unknown status NCT02078336 Phase 4 Midazolam Mylan;Lorazepam Mylan;Valium + Akineton + Dehydrobenzperidol + Atropine sulfate
19 Study on the Efficacy of Phenytoin in the Prophylaxis of Seizures of Patients With Pneumococcal Meningitis at Least 50 Yrs Old. Unknown status NCT01478035 Phase 4 Phenytoin;placebo
20 Lamotrigine Cognitive Function Study in Adult Untreated Epilepsies Completed NCT00896987 Phase 4 lamotrigine (Lamictal);Carbamazepine (Tegretol)
21 Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Single-Dose 6-Period Replicate Design (EQUIGEN Single-Dose Study) Completed NCT01733394 Phase 4 Lamotrigine Generic "A" Lamotrigine Generic "B" Lamotrigine "Brand";lamotrigine
22 Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Chronic-Dose 4-Period Replicate Design Completed NCT01713777 Phase 4 Lamotrigine Generic "A";Lamotrigine generic "B"
23 Standardized Educational Plan for Epilepsy Patients With Comorbidities Completed NCT01804322 Phase 4
24 Valproate Dose Reduction and Its Clinical Evaluation by Introducing Lamotrigine in Japanese Women With Epilepsy - Single Arm, Multicenter, and Open-label Study Completed NCT02100644 Phase 4 Lamotrigine tablets 25/100 mg
25 Methylphenidate Treatment of Attention Deficits in Epilepsy Completed NCT02178995 Phase 4 Methylphenidate
26 Cognitive and Behavioral Effects of Lacosamide Completed NCT01175954 Phase 4 Lacosamide;Lacosamide
27 RCT of the Efficacy of the Ketogenic Diet in the Treatment of Epilepsy Completed NCT00564915 Phase 4
28 Women With Epilepsy: a Pilot Study of PK and PD Anti-epileptic Drug Effects in Levonorgestrel Intrauterine System Users Completed NCT02362373 Phase 4 levonorgestrel IUS
29 Levetiracetam for Benign Rolandic Epilepsy Completed NCT00181116 Phase 4 Levetiracetam
30 Open-label, Multi-center Trial of Zonisamide as Adjunctive Therapy in Patients With Uncontrolled Partial Epilepsy Completed NCT01140867 Phase 4 zonisamide
31 A Study to Assess Tolerability and Efficacy of Topiramate Monotherapy in Recently Diagnosed Patients With Epilepsy Completed NCT01689649 Phase 4 Topiramate
32 Safety and Efficacy of Topamax Versus Carbamazepine in Benign Rolandic Epilepsy Completed NCT00216567 Phase 4 topamax
33 Randomized Controlled Trial to Assess Effects of Lacosamide on Sleep and Wake in Adults With Focal Epilepsy Completed NCT01190098 Phase 4 Lacosamide;Placebo
34 Determine Effects of Adjunctive Levetiracetam on Sleep Architecture in Adults With Partial Onset Epilepsy. Completed NCT00245713 Phase 4 levetiracetam
35 Measurement Of Serum Levels Of Two Antiepileptic Drugs During Conversion In Patients With Epilepsy Completed NCT00043914 Phase 4 lamotrigine
36 Effect of Three Different Doses of Oral Cholecalciferol on 25-Hydroxyvitamin D Changes Among Epilepsy Patients With Hypovitaminosis D Completed NCT02890823 Phase 4 Cholecalciferol
37 S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy Completed NCT00630968 Phase 4 Levetiracetam (Keppra)
38 Levetiracetam Versus Oxcarbazepine as Monotherapy to Evaluate Efficacy and Safety in Subjects With Newly or Recently Diagnosed Partial Epilepsy Completed NCT01498822 Phase 4 Levetiracetam;Oxcarbazepine
39 Study of Valproate in Young Patients Suffering From Epilepsy Completed NCT00385411 Phase 4 valproate microgranules
40 Switchability Study Between Brand and Generic Topiramate Completed NCT02113787 Phase 4
41 Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy Completed NCT00160654 Phase 4 Levetiracetam
42 Study on the Treatment of Elderly Patients With Older and Newer Antiepileptic Drugs Completed NCT00438451 Phase 4 Levetiracetam;Carbamazepine;Lamotrigine
43 Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures Completed NCT00955357 Phase 4 Lacosamide
44 Methylphenidate for Treating Attention Deficit Hyperactivity Disorder in Children With Both ADHD and Epilepsy Completed NCT00323947 Phase 4 Extended Release Methylphenidate (OROS-Methylphenidate)
45 A Study to Evaluate the Dosing, Effectiveness and Safety of Topiramate for the Treatment of Epilepsy Completed NCT00266604 Phase 4 Topiramate
46 A Phase IV-Pharmacovigilance Study of Keppra Greece - S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy Completed NCT00631150 Phase 4 Levetiracetam (Keppra)
47 Trial to Assess Optimized Dosage of Lacosamide as add-on Therapy in Patients With Partial Onset Seizure Completed NCT01235403 Phase 4 Lacosamide
48 Trial to Evaluate the Safety and Efficacy of Keppra After Conversion to Mono-therapy in Subjects With Partial Epilepsy Completed NCT00630357 Phase 4 Levetiracetam (Keppra)
49 Study on Safety and Efficacy of Levetiracetam in the Adjunctive Treatment of Female Subjects With C1 Catamenial Epilepsy Completed NCT00630630 Phase 4 Levetiracetam
50 Lamotrigine Bioequivalence Completed NCT01995825 Phase 4 lamotrigine

Search NIH Clinical Center for Epilepsy

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: epilepsy

Genetic Tests for Epilepsy

Anatomical Context for Epilepsy

MalaCards organs/tissues related to Epilepsy:

41
Temporal Lobe, Brain, Testes, Cortex, Bone, Heart, Thalamus

Publications for Epilepsy

Articles related to Epilepsy:

(show top 50) (show all 7290)
# Title Authors Year
1
Resective Surgery for Double Epileptic Foci Overlapping Anterior and Posterior Language Areas: A Case of Epilepsy With Tuberous Sclerosis Complex. ( 29867747 )
2018
2
Pseudobulbar Affect Due to Skull Base Meningioma Resolving After Temporal Lobectomy for Epilepsy. ( 29747704 )
2018
3
SPECT perfusion changes during ictal automatisms with preserved responsiveness in patients with right temporal lobe epilepsy. ( 29396356 )
2018
4
Ganglioglioma, Epilepsy, and Intellectual Impairment due to Familial TSC1 Deletion. ( 29687738 )
2018
5
Individualized prediction of seizure relapse and outcomes following antiepileptic drug withdrawal after pediatric epilepsy surgery. ( 29446447 )
2018
6
Re: Field testing of ICHD-3 beta criteria of periictal headache in patients with focal epilepsy - a prospective diary study. ( 29754499 )
2018
7
Progressive myoclonus epilepsy without renal failure in a Chinese family with a novel mutation in SCARB2 gene and literature review. ( 29605618 )
2018
8
Allocation of Treatment Responsibility in Adolescents With Epilepsy: Associations With Cognitive Skills and Medication Adherence. ( 29447360 )
2018
9
Magnetic resonance imaging of tuberous sclerosis complex with or without epilepsy at 7A T. ( 29869697 )
2018
10
Focal Epilepsy in a Teenager With Facial Atrophy and Hair Loss. ( 29961525 )
2018
11
Retinal Neuronal Loss in Visually Asymptomatic Patients With Myoclonic Epilepsy With Ragged-Red Fibers. ( 29979334 )
2018
12
TOP3B: A Novel Candidate Gene in Juvenile Myoclonic Epilepsy? ( 29490292 )
2018
13
Anti-epileptogenic and Anti-convulsive Effects of Fingolimod in Experimental Temporal Lobe Epilepsy. ( 29934763 )
2018
14
Predictive value of preoperative statistical parametric mapping of regional glucose metabolism in mesial temporal lobe epilepsy with hippocampal sclerosis. ( 29247965 )
2018
15
Widespread abnormalities in white matter integrity and their relationship with duration of illness in temporal lobe epilepsy. ( 29881803 )
2018
16
A novel mutation in LAMC3 associated with generalized polymicrogyria of the cortex and epilepsy. ( 29247375 )
2018
17
Childhood-onset generalized epilepsy in Bainbridge-Ropers syndrome. ( 29367179 )
2018
18
Epileptiform activity in traumatic brain injury predicts post-traumatic epilepsy. ( 29537656 )
2018
19
Differential patterns of dynamic functional connectivity variability of striato-cortical circuitry in children with benign epilepsy with centrotemporal spikes. ( 29206330 )
2018
20
High prevalence of epilepsy in two rural onchocerciasis endemic villages in the Mahenge area, Tanzania, after 20A years of community directed treatment with ivermectin. ( 29921319 )
2018
21
Multimodal Imaging in Extratemporal Epilepsy Surgery. ( 29796351 )
2018
22
New-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES): State of the art and perspectives. ( 29476535 )
2018
23
Cardiac arrhythmia and neuroexcitability gene variants in resected brain tissue from patients with sudden unexpected death in epilepsy (SUDEP). ( 29619247 )
2018
24
Losigamone add-on therapy for focal epilepsy. ( 29355908 )
2018
25
Attention profiles in childhood absence epilepsy compared with attention-deficit/hyperactivity disorder. ( 28992996 )
2018
26
[<sup>18</sup>F]GE180 positron emission tomographic imaging indicates a potential double-hit insult in the intrahippocampal kainate mouse model of temporal lobe epilepsy. ( 29364511 )
2018
27
Whole-exome sequencing to disentangle the complex genetics of hippocampal sclerosis-temporal lobe epilepsy. ( 29904719 )
2018
28
Tolerability of a comprehensive cardiorespiratory monitoring protocol in an epilepsy monitoring unit. ( 29981497 )
2018
29
Progressive topological disorganization of brain network in focal epilepsy. ( 29344935 )
2018
30
Magnetoencephalographic imaging of ictal high-frequency oscillations (80-200A Hz) in pharmacologically resistant focal epilepsy. ( 29111591 )
2018
31
Increased risk of hospital admission for ICD-9-CM psychotic episodes following admission for epilepsy. ( 29974458 )
2018
32
Algorithm for automatic detection of spontaneous seizures in rats with post-traumatic epilepsy. ( 29936072 )
2018
33
New onset epilepsy among patients with periodic discharges on continuous electroencephalographic monitoring. ( 29974460 )
2018
34
Oxidative stress in patients with refractory temporal lobe epilepsy and mesial temporal sclerosis: Possible association with major depressive disorder? ( 29414551 )
2018
35
Identification of a Novel Homozygous Splice-Site Mutation in <i>SCARB2</i> that Causes Progressive Myoclonus Epilepsy with or without Renal Failure. ( 29941711 )
2018
36
GRIN2A mutations in epilepsy-aphasia spectrum disorders. ( 29056244 )
2018
37
Rare variants and de novo variants in mesial temporal lobe epilepsy with hippocampal sclerosis. ( 29904720 )
2018
38
Long-term surveillance of SUDEP in drug-resistant epilepsy patients treated with VNS therapy. ( 29336017 )
2018
39
Susceptibility-weighted and diffusion kurtosis imaging to evaluate encephalomalacia with epilepsy after traumatic brain injury. ( 29761118 )
2018
40
Reflex epilepsy: triggers and management strategies. ( 29403278 )
2018
41
Increased cardiac stiffness is associated with autonomic dysfunction in patients with temporal lobe epilepsy. ( 29697139 )
2018
42
Myoclonus epilepsy, retinitis pigmentosa, leukoencephalopathy and cerebral calcifications associated with a novel m.5513G&amp;gt;A mutation in the MT-TW gene. ( 29625105 )
2018
43
Spike-related haemodynamic responses overlap with high frequency oscillations in patients with focal epilepsy. ( 29360943 )
2018
44
Abnormal default-mode network homogeneity in patients with temporal lobe epilepsy. ( 29952987 )
2018
45
MR Fingerprinting: An Advance for Patients with Temporal Lobe Epilepsy. ( 29916775 )
2018
46
Refractory epilepsy in Norrie disease. ( 29725776 )
2018
47
Association between SCN1A gene polymorphisms and drug resistant epilepsy in pediatric patients. ( 29353705 )
2018
48
Temporal lobe encephalocele, a subtle structural lesion that can be associated with temporal lobe epilepsy. ( 29525398 )
2018
49
Seizures and Tumor Progression in Glioma Patients with Uncontrollable Epilepsy Treated with Perampanel. ( 29970574 )
2018
50
mTOR dysregulation and tuberous sclerosis-related epilepsy. ( 29338461 )
2018